ZVRA
ZEVRA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.61
−1.94%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $0.14
- Revenue estimate
- $37.1M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $0.14
- EPS estimate
- $0.11
- Revenue actual
- $39.7M
- Revenue estimate
- $33.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +149.7%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $24
- PT range
- $20 – $28
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $0.11 | $0.14 | Beat 27.27% | $39.7M |
| May 6, 2026 | $0.06 | $0.18 | Beat 200.00% | $36.2M |
| Mar 9, 2026 | $0.05 | $0.21 | Beat 321.43% | $34.1M |
| Nov 5, 2025 | -$0.02 | -$0.01 | Beat 50.00% | $26.1M |
| Aug 12, 2025 | $2.19 | $1.21 | Miss -44.75% | $25.9M |
| Mar 11, 2025 | -$0.39 | -$0.67 | Miss -71.79% | $12.0M |
| Aug 14, 2023 | -$0.39 | -$0.15 | Beat 61.54% | $8.5M |
| May 15, 2023 | -$0.26 | -$0.34 | Miss -30.77% | $2.9M |
| Mar 7, 2023 | -$0.21 | -$0.26 | Miss -23.81% | $2.3M |
| Aug 11, 2022 | -$0.12 | -$0.19 | Miss -58.33% | $1.3M |
| May 12, 2022 | -$0.05 | -$0.05 | In line | $4.0M |
| Nov 10, 2021 | -$0.07 | -$0.05 | Beat 28.57% | $2.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026